<DOC>
	<DOCNO>NCT01533259</DOCNO>
	<brief_summary>This study evaluate efficacy Stribild® ( elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate ( EVG/COBI/FTC/TDF ) ) single-tablet regimen ( STR ) switch regimen consist raltegravir plus Truvada® ( FTC/TDF ) baseline maintain HIV-1 RNA &lt; 50 copies/mL Week 12 virologically suppress , HIV-1 infect adult . This study also evaluate safety , tolerability , efficacy Stribild 24 48 week treatment .</brief_summary>
	<brief_title>Open-Label Pilot Study Evaluate Switching From Regimen Consisting Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen Virologically Suppressed , HIV-1 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Ability understand sign write informed consent form Virologically stable current first antiretroviral regimen consist raltegravir twice daily plus FTC/TDF continuously ≥ 6 month precede screen visit document undetectable plasma HIV1 RNA level ≥ 6 month precede screen visit ( measure least twice use assay ) never experience two consecutive HIV1 RNA detectable level first achieve confirm HIV1 RNA level detectable level first regimen HIV1 RNA &lt; 50 copies/mL screen visit Have genotype prior start initial antiretroviral therapy know resistance study agent time Normal ECG Hepatic transaminases ≤ 5 x upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL Adequate hematologic function Serum amylase ≤ 5 x ULN Estimated glomerular filtration rate ≥ 70 mL/min Females childbearing potential must agree utilize highly effective contraception method nonheterosexually active , practice sexual abstinence vasectomize partner screen throughout duration study period 30 day follow last dose study drug Females utilize hormonal contraceptive one birth control method must use method least three month prior study dose Males must agree utilize highly effective method contraception heterosexual intercourse screen visit , throughout duration study 30 day follow discontinuation investigational medicinal product must non heterosexually active , practice sexual abstinence , vasectomize New AIDS define condition diagnose within 21 day prior screen Females breastfeed Positive serum pregnancy test ( female childbearing potential ) Individuals acute chronic hepatitis B hepatitis C coinfection Individuals experience decompensated cirrhosis Have implant defibrillator pacemaker Current alcohol substance abuse would interfere compliance A history malignancy within past 5 year ongoing malignancy cutaneous Kaposi 's sarcoma , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma Active , serious infection require parenteral antibiotic antifungal therapy within 21 day prior baseline visit Receiving investigational drug Participation clinical trial without prior approval sponsor Have treat immunosuppressant therapy chemotherapeutic agent within 3 month study screening , expect receive agent systemic steroid study Any clinical condition prior therapy would make individual unsuitable study unable comply dose requirement Receiving ongoing therapy anticipate need initiate drug herbal/natural supplement study contraindicate recommend use , include drug use Stribild ; individual know allergy excipients Stribild single tablet regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>